LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair (LUCY)
The LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The LUCY Study is a prospective, consecutively enrolling, non-randomized multi center post-market registry to evaluate the Ovation Abdominal Stent Graft Platform when used in the endovascular treatment of female patients.
The primary endpoint is the Major Adverse Event (MAE) rate within 30 days of the initial procedure. MAEs will be adjudicated and reported based upon an independent Clinical Events Committee (CEC).
Secondary endpoints of the study will be achieved by demonstrating the benefits in female patients (Treatment Group) are comparable to male patients (Control Group) despite the fact that historically fewer female patients have been eligible for EVAR, and they have experienced a higher rate of access-related complications and higher mortality rates. Secondary endpoints will be evaluated through 1 year (365 ± 60 days) post-procedure.
A maximum of 45 sites across the United States are expected to enroll 225 subjects (75 females in the Treatment Group and 150 males in the Control Group).
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is > 18 years of age.
- Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study).
- Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form.
- Patient is considered by the treating physician to be a candidate for elective open surgical repair of the AAA (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification; refer to Appendix II: ASA Classification System). ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:
- Abdominal aortic aneurysm >5.0 cm in diameter;
- Aneurysm has increased in size by 0.5 cm in last 6 months; or
- Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment.
Patient has suitable anatomy that allows use of the TriVascular Ovation Abdominal Platform:
- Iliac or femoral arteries that allow endovascular access with the TriVascular Ovation Abdominal Platform.
- Proximal aortic neck landing zone with an inner wall diameter of no less than 16 mm and no greater than 30 mm at 13 mm below the inferior renal artery.
- Distal iliac artery landing zone length (seal zone) of ≥10 mm. The resultant repair should preserve patency in at least one hypogastric artery.
- Distal iliac artery landing zone an inner wall diameter of no less than 8 mm and no greater than 25 mm.
- Distance from the most distal renal artery to most superior internal iliac artery measurement is at least 130 mm.
- Aortic angle of ≤ 60 degrees if proximal neck length is ≥10 mm and ≤ 45 degrees if proximal neck length is <10 mm.
- Patient must be willing to comply with all required follow-up exams.
Exclusion Criteria
- Patient has a need for emergent surgery.
- Patient has a dissecting aneurysm.
- Patient has an acutely ruptured aneurysm.
- Patient has an acute vascular injury.
- Patient has had a previous repair of the abdominal aortic aneurysm or an iliac artery in intended treatment zone.
- Patient has a known thoracic aortic aneurysm or dissection that will require treatment (surgery or endovascular intervention) within the study period.
- Patient has a mycotic aneurysm or has an active systemic infection.
- Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina).
- Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6 months.
- Patient requires use of techniques (e.g. Chimney graft) that would cover the renal arteries.
- Patient requires planned adjunctive devices (e.g. renal stents) to complete the procedure.
- Patient has a major surgical or interventional procedure planned during or within ±30 days of the AAA repair.
- Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
- Patient has history of bleeding disorders or refuses blood transfusions.
- Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0 mg/dl
- Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
- Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol.
- Patient has a body habitus that would inhibit X-ray visualization of the aorta.
- Patient has a limited life expectancy of less than 1 year.
- Patient is currently participating in an investigational device or drug clinical trial.
- Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Female (Treatment Group)
Device: Ovation Abdominal Stent Graft Platform
|
|
|
Male (Control Group)
Device: Ovation Abdominal Stent Graft Platform
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Major Adverse Event (MAE)
Time Frame: 1 month (30 ± 10 days)
|
1 month (30 ± 10 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serious and Non-Serious Adverse Events
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Access-related vascular complications
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Technical (deployment) success
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Freedom from Type I & III endoleaks
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Freedom from migration
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Freedom from aneurysm enlargement
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Freedom from AAA rupture
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Freedom from conversion to open repair
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Freedom from AAA related secondary interventions
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Freedom from mortality (all cause and AAA related)
Time Frame: 1 year (365 ± 60 days)
|
1 year (365 ± 60 days)
|
|
|
Clinical Utility, including:
Time Frame: 1 year (365 ± 60 days)
|
Blood loss, including if transfusion required, Duration of procedure, Length of hospital and ICU (if required) stay, Anesthesia type
|
1 year (365 ± 60 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jennifer Ash, MD, Christie Clinic Vein & Vascular Center
- Study Chair: Venita Chandra, MD, Stanford School of Medicine
- Study Chair: Eva Rzucidlo, MD, Geisel School of Medicine, Dartmouth
- Study Chair: Ageliki Vouyouka, MD, Mount Sinai Hospital
- Study Chair: Monica Hunter, MD, Ohio Heart and Vascular Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 771-0016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Aortic Aneurysm
-
NCT07577128Active, not recruitingAortic Aneurysm | Aortic Aneurysm Abdominal | Abdominal Aneurysm
-
NCT04252573Active, not recruiting1 Paravisceral Abdominal Aortic Aneurysm | 2 Juxtarenal Abdominal Aortic Aneurysm | 3 Pararenal Abdominal Aortic Aneurysm | 4 Complex Abdominal Aortic Aneurysms
-
NCT02225756UnknownSmall Abdominal Aortic Aneurysm | Abdominal Aortic Aneurysm,
-
NCT04269447Enrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without Rupture
-
NCT07475260Not yet recruitingAbdominal Aortic Aneurysm | Endovascular Abdominal Aortic Aneurysm Repair | Fenestrated Endovascular Aortic Repair
-
NCT07330752RecruitingAneurysm, Abdominal Aortic
-
NCT07548099Recruiting
-
NCT07476196RecruitingAbdominal Aortic Aneurysm
-
NCT07473102RecruitingAbdominal Aortic Aneurysm
-
NCT07511101CompletedAAA - Abdominal Aortic Aneurysm
Clinical Trials on Ovation Abdominal Stent Graft Platform
-
NCT01092117CompletedAortic Aneurysm, Abdominal
-
NCT02949297Completed
-
NCT02451566CompletedAbdominal Aortic Aneurysm
-
NCT01980901CompletedAortic Aneurysm, Abdominal
-
NCT05172830RecruitingAbdominal Aortic Aneurysm
-
NCT01097772CompletedAbdominal Aortic Aneurysm
-
NCT00816062CompletedAortic Aneurysm, Abdominal